We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis.
- Authors
Hill-Cawthorne, Grant A; Button, Tom; Tuohy, Orla; Jones, Joanne L; May, Karen; Somerfield, Jennifer; Green, Alison; Giovannoni, Gavin; Compston, D Alastair S; Fahey, Michael T; Coles, Alasdair J
- Abstract
Alemtuzumab is a lymphocyte depleting monoclonal antibody that has demonstrated superior efficacy over interferon β-1a for relapsing-remitting multiple sclerosis (MS), and is currently under investigation in phase 3 trials. One unresolved issue is the duration and significance of the lymphopenia induced. The long term effects on lymphocyte reconstitution of a single course, and the consequences that this has on disability, morbidity, mortality and autoimmunity, were examined.
- Publication
Journal of neurology, neurosurgery, and psychiatry, 2012, Vol 83, Issue 3, p298
- ISSN
1468-330X
- Publication type
Journal Article
- DOI
10.1136/jnnp-2011-300826